Cytyc (CYTC), a diagnostics/device company that focuses on women's health and cancer, will pay $452 million ($24 per share) to buy Adeza Biomedical (ADZA). The main product for Adeza is FullTerm, The Fetal Fibronectin Test which identifies women at risk for preterm birth. Currently, FullTerm produces revenue of about $50 million, but Cytyc estimates it has potential for $500 million annually, given Cytyc's already existing OB/GYN sales force. Cytyc expects the purchase to be neutral to earnings in 2007 and to add 5 cents in 2008. Cytyc rose 73 cents to $30.28, a 2.5% gain, while Adeza shot 53% higher, climbing $8.25 to end at $23.78. Diversa (DVSA), a maker of enzymes and biological compounds, will exchange $154.7 million worth of stock to acquire Celunol, a company developing cellulosic ethanol. The ethanol is produced from biomass using enzymes, instead of the traditional process that employs natural gas.